KR102947706B1 - 암 치료를 위한 제약 조합물 - Google Patents

암 치료를 위한 제약 조합물

Info

Publication number
KR102947706B1
KR102947706B1 KR1020217012004A KR20217012004A KR102947706B1 KR 102947706 B1 KR102947706 B1 KR 102947706B1 KR 1020217012004 A KR1020217012004 A KR 1020217012004A KR 20217012004 A KR20217012004 A KR 20217012004A KR 102947706 B1 KR102947706 B1 KR 102947706B1
Authority
KR
South Korea
Prior art keywords
delete delete
sfrp2
antibody
weeks
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217012004A
Other languages
English (en)
Korean (ko)
Other versions
KR20210065146A (ko
Inventor
낸시 드모어
Original Assignee
무스크 파운데이션 포 리서치 디벨롭먼트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 무스크 파운데이션 포 리서치 디벨롭먼트 filed Critical 무스크 파운데이션 포 리서치 디벨롭먼트
Publication of KR20210065146A publication Critical patent/KR20210065146A/ko
Application granted granted Critical
Publication of KR102947706B1 publication Critical patent/KR102947706B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217012004A 2018-09-27 2019-09-27 암 치료를 위한 제약 조합물 Active KR102947706B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862737155P 2018-09-27 2018-09-27
US62/737,155 2018-09-27
PCT/US2019/053651 WO2020069439A1 (en) 2018-09-27 2019-09-27 Pharmaceutical combination for the treatment of cancer

Publications (2)

Publication Number Publication Date
KR20210065146A KR20210065146A (ko) 2021-06-03
KR102947706B1 true KR102947706B1 (ko) 2026-04-03

Family

ID=69953118

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217012004A Active KR102947706B1 (ko) 2018-09-27 2019-09-27 암 치료를 위한 제약 조합물

Country Status (12)

Country Link
US (1) US20210395351A1 (cg-RX-API-DMAC10.html)
EP (1) EP3856784A4 (cg-RX-API-DMAC10.html)
JP (1) JP7451506B2 (cg-RX-API-DMAC10.html)
KR (1) KR102947706B1 (cg-RX-API-DMAC10.html)
CN (2) CN119818670A (cg-RX-API-DMAC10.html)
AU (1) AU2019351267B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021005525A2 (cg-RX-API-DMAC10.html)
CA (1) CA3114173A1 (cg-RX-API-DMAC10.html)
IL (1) IL281782A (cg-RX-API-DMAC10.html)
MX (1) MX2021003274A (cg-RX-API-DMAC10.html)
SG (1) SG11202102865WA (cg-RX-API-DMAC10.html)
WO (1) WO2020069439A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021013222A (es) * 2019-05-03 2022-01-06 Genentech Inc Metodos para tratar el cancer con un anticuerpo anti-pd-l1.
WO2025199292A1 (en) * 2024-03-21 2025-09-25 Musc Foundation For Research Development A humanized monoclonal antibody to sfrp2 for tumor associated macrophage reduction and polarization in cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011119524A1 (en) 2010-03-22 2011-09-29 The University Of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
WO2017025016A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
US20170145071A1 (en) 2015-11-02 2017-05-25 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
JP2018527299A (ja) 2015-06-24 2018-09-20 ヤンセン バイオテツク,インコーポレーテツド Cd38を特異的に結合する抗体による免疫調節及び固形腫瘍の治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2285989B1 (en) 2008-05-15 2016-11-16 The University of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
WO2014022774A1 (en) 2012-08-02 2014-02-06 Fred Hutchinson Cancer Research Center Treatment induced damage to the tumor micro-environment promotes cancer therapy resistance through extracellular proteins
HK1254404A1 (zh) * 2015-06-25 2019-07-19 Advanced Accelerator Applications 治疗过度表达生长抑素受体的神经内分泌肿瘤的方法
PL3964529T3 (pl) * 2016-01-22 2025-10-27 MabQuest SA Nieblokujące przeciwciała specyficzne względem pd1
CN110267682A (zh) * 2017-02-14 2019-09-20 诺华股份有限公司 Wnt抑制剂和抗PD-1抗体分子组合的给药方案

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011119524A1 (en) 2010-03-22 2011-09-29 The University Of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
JP2018527299A (ja) 2015-06-24 2018-09-20 ヤンセン バイオテツク,インコーポレーテツド Cd38を特異的に結合する抗体による免疫調節及び固形腫瘍の治療
WO2017025016A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CN108473977A (zh) 2015-08-10 2018-08-31 信达生物制药(苏州)有限公司 Pd-1抗体
US20170145071A1 (en) 2015-11-02 2017-05-25 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment

Also Published As

Publication number Publication date
BR112021005525A2 (pt) 2021-06-29
CN113454114A (zh) 2021-09-28
WO2020069439A1 (en) 2020-04-02
IL281782A (en) 2021-05-31
CN119818670A (zh) 2025-04-15
US20210395351A1 (en) 2021-12-23
JP2022502434A (ja) 2022-01-11
MX2021003274A (es) 2021-09-28
SG11202102865WA (en) 2021-04-29
CA3114173A1 (en) 2020-04-02
EP3856784A1 (en) 2021-08-04
EP3856784A4 (en) 2022-10-19
CN113454114B (zh) 2024-12-27
AU2019351267A1 (en) 2021-05-13
JP7451506B2 (ja) 2024-03-18
AU2019351267B2 (en) 2026-07-23
KR20210065146A (ko) 2021-06-03

Similar Documents

Publication Publication Date Title
AU2018351006B2 (en) Anti-CD47 agent-based ovarian cancer therapy
JP7681401B2 (ja) がん処置のためのaxl特異的抗体
KR20150130318A (ko) 암의 치료에 클라우딘 18.2에 대한 항체를 이용하는 치료법
JP7548924B2 (ja) がんの処置における増強された有効性のためのil-4/il-13経路阻害剤
KR20220007593A (ko) 암 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용
KR20120083359A (ko) EpCAMxCD3 이중특이성 항체를 투여하기 위한 투약 용법
EA037613B1 (ru) Гуманизированные антитела против ceacam1
US20210047416A1 (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
JP2025060639A (ja) Pd-1/pd-l1シグナル伝達阻害剤に不応答性のがんの処置方法および医薬
WO2017165125A1 (en) Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer
KR102693317B1 (ko) 암 면역요법을 위한, 활성화되고 확장된 자연 킬러 세포와 조합된 항-cxcr4 항체
CN118871467A (zh) 抗pd-l2抗体
JP7451506B2 (ja) がんの治療用の薬学的組合せ
US20220025036A1 (en) Use of il-1beta binding antibodies
EP3440111B1 (en) Anti-vegfr-1 antibodies and uses thereof
JP2025542297A (ja) 肺癌の組み合わせ療法
RU2838216C2 (ru) Фармакологическая комбинация для лечения рака
HK40122434A (en) Pharmaceutical combination for the treatment of cancer
RU2836467C2 (ru) Ингибиторы пути il-4/il-13 для повышенной эффективности при лечении злокачественных новообразований
US20210009672A1 (en) Methods of treating or preventing liver fibrosis with inhibition of activins a & b

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)